. However, further attention should be given to patients with ICD since electrical shocks introduced during treatment, even if appropriate, might lead to a deterioration in cardiac function (Poole et al., 2008) . Furthermore, a worsening of heart failure or the patient's condition can also cause arrhythmic episodes (Pedersen et al., 2014) . Therefore, identifying high-risk patients experiencing MVAE and HHF is crucial for improving survival in ICM and NICM patients with ICD.
The utility of cardiac magnetic resonance with late gadolinium enhancement technique (LGE-CMR) was established while stratifying the risk of MVAE or HHF in patients with cardiomyopathy (Fujita et al., 2015; Konno et al., 2014; Scott, Rosengarten, Curzen, & Morgan, 2013) . Currently, patients with magnetic resonance imaging -safe ICDs can undertake LGE-CMR if they satisfy certain requirements (Gold et al., 2015) , but not all patients who require ICD implantation can appreciate the benefit of MRI-safe ICD because of facility criteria or the requirement of device experts. Furthermore, LGE-CMR may not be always available and involves significant cost. Therefore, simple and cost-effective modalities are still warranted in discriminating the risk of cardiac events in patients with ICM or NICM who have received an ICD. From this perspective, a simple and cost-effective 12-lead ECG may be used to assess high-risk patients for MVAE and HHF. Various parameters, such as QRS duration, bundle branch blocks, fragmented QRS, and T-wave alternans have been reported to be useful in the prediction of MVAE in patients with cardiomyopathy (Goldberger, Subačius, Patel, Cunnane, & Kadish, 2014) .
Although the lead aVR is often neglected in daily clinical practice, ST elevation in lead aVR has been reported to be useful in the prediction of left main trunk involvement in ischemic heart disease and aortic dissection (Kireyev, Arkhipov, Zador, Paris, & Boden, 2010; Riera et al., 2011; Yan et al., 2007) . Similarly, there is an increasing notion that T wave amplitude in the lead aVR (TAaVR) >0 mV (known as upright T wave) may be used as a prognostic tool in patients with postmyocardial infarction, in those with renal failure who undergo hemodialysis, and in male patients (Jaroszyński et al., 2015; Tan, Engel, Myers, Sandri, & Froelicher, 2008; Torigoe et al., 2012) . However, few reports have demonstrated the ability of TAaVR to predict cardiac events, including MVAE and HHF in ICM and NICM patients with ICD.
The purpose of this study was to investigate the ability of TAaVR to predict cardiac events in ICM and NICM patients with ICD.
| METHODS

| Study population
This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Bioethical Committee on Medical Research, School of Medicine, Kanazawa University. We studied ICM and NICM patients who newly underwent ICD implantation, ICD exchange or ICD follow-up between January 2009 and December 2015 in Kanazawa University Hospital. ICM and NICM were diagnosed based on clinical and genetic data. Secondary cardiomyopathy, such as cardiac sarcoidosis and hypertensive heart disease, were included in this study. Patients with Brugada syndrome, long QT syndrome, J wave syndrome, idiopathic ventricular fibrillation, idiopathic ventricular tachycardia, and coronary spastic angina were excluded from the study. Additionally, patients with complete left bundle branch block or right ventricular pacing were excluded since TAaVR was known to be upright in these settings (Verma, 2003) .
Patients follow-up occurred for up to 36 months.
| ICD interrogation, ICD therapy and patient follow-up
The primary endpoint was defined as composite cardiac events that included cardiac death, MVAE, or HHF. Cardiac death, MVAE, and HHF were evaluated, respectively, as secondary endpoints. Due to the relatively small number of subjects, we evaluated the primary endpoint and secondary endpoint separately. Cardiac events were retrospectively collected using the medical record system and/or device interrogation. Device interrogation was performed in the outpatient clinic routinely every 3-6 months, or whenever symptomatic events that were related to ventricular tachycardia or ICD shock delivery happened. All devices were programmed to monitor or deliver shocks during arrhythmic episodes. Information on MVAE, including sustained VT or VF requiring adequate ICD shock delivery or antitachycardia pacing, were obtained. Inadequate shock events were not included in MVAE.
| Evaluation of electrocardiogram findings
A standard 12-lead electrocardiogram (ECG; 0.5-150 Hz, 25 mm/s, 10 mm/mV) was recorded in the supine position during quiet respiration (NIHON KOHDEN, Cardiofax V; model ECG-1550K, or FUKUDA DENSHI, CardioMax; model FX-8222). Conventional ECG parameters included heart rate, bundle branch block, atrioventricular block, QRS axis deviation, abnormal Q waves, PR interval, QRS duration, QT duration, T wave inversion, left ventricular hypertrophy (Sokolow & Lyon, 1949) , and fragmented QRS (fQRS). The T-wave axis was estimated in the same manner as the estimation of QRS axis deviation (Salles, Xavier, Sousa, Hasslocher-Moreno, & Cardoso, 2004) . Abnormal Q wave was defined as a Q wave with more than 25% of the QRS complex depth in at least two contiguous leads except aVR (Konno et al., 2004 ). An isolated abnormal Q wave was not defined as an abnormal Q wave in this study. Likewise, T wave inversion was defined as a negative T wave (T amp <0 mV) in at least two contiguous leads except aVR, V 1 , and V 2 (Konno et al., 2007 ). An isolated T wave inversion was not defined as a T wave inversion in this study. QTc was calculated using Bazett`s formula. fQRS in patients with narrow QRS (<120 ms) and wide QRS (≥120 ms) were defined on the basis of previous studies (Das, Khan, Jacob, Kumar, & Mahenthiran, 2006; Das et al., 2008) .
In addition to these conventional parameters, TAaVR was analyzed. T-wave amplitude was defined as the first deflection after the QRS complex and/or the maximum deviation from the PR isoelectric baseline (Yan et al., 2007) . TAaVR was measured manually. The cut-off value in TAaVR was set at −0.1 mV for this study. Previously, Okuda et al. (2011) reported that a cut-off value of −0.1 mV could predict allcauses of death in heart failure patients with narrow QRS complexes when the TAaVR <−0.1 mV was considered a reference. Thus, normal TAaVR was defined as TAaVR <−0.1 mV, while less negative TAaVR was defined as −0.1 mV ≤ TAaVR < 0 mV and 0 mV ≤ TAaVR. Figure 1 demonstrates representative ECGs of normal TAaVR (left, arrow) and less negative TAaVR (right, asterisk).
| Echocardiography
Echocardiographic studies were performed using IE33 Ultrasound System (Phillips Healthcare, DA Best, The Netherlands). End-diastolic left ventricular diastolic diameter (LVDd), end-systolic left ventricular systolic diameter (LVDs), and end-diastolic septal wall thickness (SWT)
were evaluated using parasternal long-axis view images. Left ventricular ejection fraction (LVEF) was calculated using Teichholz`s formula.
| Statistical analysis
Basic characteristics of the study population were compared between the positive composite endpoint group and that of the negative group.
Categorical data are shown as frequency and percentage, whereas continuous variables are shown as median and interquartile range (IQR). Categorical variables were compared using the Chi-square test.
Continuous variables were compared using Wilcoxon rank-sum test.
A receiver-operating characteristics (ROC) curve was used to estimate the ability of TAaVR to predict primary endpoint. The cut-off point was determined using the Youden index (Youden, 1950) .
Univariate and multivariate Cox regression analysis was performed to evaluate factors associated with the composite endpoint. Variables with p < .1 on univariate analysis were chosen in multivariate Cox regression analysis. According to the triangle of Einthoven, aVR is calculated by the following formula, −1/2 (I + II). Therefore, T wave amplitudes in leads I and II were also measured manually, which were likewise included in the univariate Cox regression analysis.
A Kaplan-Meier Curve was used to estimate the event-free survival rate per the primary endpoint and each secondary endpoint (cardiac death, MVAE, and HHF), with comparison of groups by the log-rank test. A p value <.05 was assumed to indicate statistical significance. Statistical analysis was performed using statistical software JMP ® Pro 11 (SAS Institute Inc., Cary, NC, USA). months. During the study period, a primary endpoint was observed in 37 of 93 subjects (39.8%). Among these subjects, cardiac death was observed as a secondary endpoint in five subjects (5.4%), MVAE was observed as a secondary endpoint in 28 subjects (30.1%), and HHF was observed as a secondary endpoint in 16 subjects (17.2%).
| RESULTS
| Patient characteristics
Basic characteristics of the study population are described in Table 1 .
The median age of the study population was 64 years, and 77.4% of subjects were male. ICD implantation as a secondary prevention occurred in 76.3% and there was a notable trend (p = .06) of difference between F I G U R E 1 Representative ECGs of normal negative T wave amplitude and less negative T wave amplitude in lead aVR. Normal negative TAaVR (arrow) and less negative TAaVR (asterisk) are shown. TAaVR indicates T wave amplitude in lead aVR the event-positive group and event-negative group. The study population included 61 (65.6%) NICM patients (dilated cardiomyopathy, n = 14;
hypertrophic cardiomyopathy, n = 35; arrhythmogenic right ventricular cardiomyopathy, n = 4; cardiac sarcoidosis, n = 6; and Emery-Dreifuss muscular dystrophy, n = 2). The usage of diuretics was more frequent in the event-positive group than in the event-negative group.
Electrocardiographic and echocardiographic findings are provided in T A B L E 1 Basic characteristics of the study population
| DISCUSSION
This study provides two major findings. First, less negative TAaVR was an independent predictor for the primary endpoint. Second, less negative TAaVR was significantly associated with MVAE in secondary endpoints.
An upright T wave (TAaVR > 0 mV) is generally accepted to be a useful ECG parameter for cardiac events in males, in patients following a myocardial infarction, and in hemodialysis patients (Jaroszyński et al., 2015; Tan et al., 2008; Torigoe et al., 2012) . However, high-risk patients were appropriately excluded when the cut-off value was set at −0.1 mV, as was done in the present study and as was shown in previous studies (Okuda et al., 2011) . Okuda et al. (2011) enrolled heart failure patients with a narrow QRS complex in their study and, in doing so, revealed that less negative TAaVR was an independent predictor of mortality. Similarly, in our study, most patients that experienced complications with chronic heart failure were at high risk for cardiovascular events. Therefore, −0.1 mV is considered to be an appropriate cut-off value in ICM or NICM patients with ICD.
In modern ECG machines, aVR is not measured but calculated using leads I and II; aVR = −1/2 (I + II). Therefore, less negative T wave amplitude in aVR reflects the presence of T wave inversion in at least leads I and/or II. Although, less negative TAaVR was significantly associated with the primary endpoint in this study, T wave amplitude in leads I and II did not predict the primary endpoint. These findings suggest that a single lead did not have enough predictive value for the primary endpoint, but that averaging the T wave amplitudes in leads I and II (aVR)
could provide enough predictive power to predict the primary endpoint. This could be partly because TAaVR may provide information on a wide range of electrophysiological activities in the inferolateral part of the left ventricle compared to each lead, I and II, thus, less negative TAaVR or upright T wave might reciprocally reflect ST-segment depression and/or T wave inversion in the inferolateral regions (Tanaka et al., 2016) . Additionally, compared to other ECG variables, TAaVR has the unique advantage of being a single lead that can provide sufficient information regarding the entirety of the heart with the exception of the anterior regions. This characteristic feature of TAaVR on a simple and AVB, atrioventricular block; CRBBB, complete right bundle branch block; LVDd, left ventricular enddiastolic diameter; LVDs, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; SWT, end-diastolic ventricular septal wall thickness; TA, T wave amplitude, TAaVR, T wave amplitude in lead aVR. Less negative TAaVR was defined as −0.1 mV ≤ TAaVR < 0 mV and 0 mV ≤ TAaVR.
T A B L E 2 Electrocardiographic and Echocardiographic findings
cost-effective ECG may enable us to identify high-risk ICM or NICM patients with ICD.
For predicting secondary endpoints, less negative TAaVR was successful in predicting the event-free survival rate of MVAE (Figure 3 ). Previous reports have demonstrated that TAaVR is strongly associated with cardiac death or sudden cardiac death that is presumably caused by MVAE (Jaroszyński et al., 2015; Okuda et al., 2011; Tan et al., 2008) , which is consistent with our data.
Meanwhile, Shinozaki, Tamura, & Kadota (2011) T A B L E 3 Risk factors for primary endpoint F I G U R E 2 Kaplan-Meier curve analysis of the primary endpoint. The event-free survival rate at the primary endpoint was compared between the two groups (i.e., patients with TAaVR <−0.1 mV and patients with less negative TAaVR, −0.1 mV ≤ TAaVR <0 mV and 0 mV ≤ TAaVR). Patients with less negative TAaVR showed significantly worse outcomes compared to those with TAaVR < −0.1 mV (p < .01). Three-year event free survival rates in patients with TAaVR < −0.1 mV and those with less negative TAaVR were 85.2% and 45.8%, respectively not predict the occurrence of HHF in our study population. The main reason for this discrepancy includes the involvement of patients who previously experienced myocardial infarction with severe left ventricular remodeling and left ventricular systolic impairment in the study by Shinozaki et al. (2011) . In addition, this discrepancy might be explained by the lack of statistical power for detecting significant difference between the two groups due to the small number of our study population.
There are several limitations to this study. First, the study population in our study was heterogeneous. We enrolled ICM and NICM patients with ICD in this study. For example, patients with ICM constituted 35.5% of the study population. This percentage indicates a significant etiological difference between cardiomyopathy in patients in Japanese and Western countries (Group JJW, 2013) . Furthermore, most patients underwent ICD implantation for secondary prevention (76.3%). Therefore, it might be difficult to apply our results to the general ICM and NICM population or to patients who received ICD for primary prevention. Additionally, patients with continuous ventricular pacing and left bundle branch block were excluded from this study.
Nonetheless, multiple Cox regression analyses suggested that less negative TAaVR could be a useful marker for cardiac events despite our heterogeneous cardiomyopathy population. Second, the sample size was small. The significant correlations between less negative
TAaVR and cardiac events observed in this study should be validated in a larger cohort. This validation would also address the limitations inherent to a retrospective study design. Indeed, future studies that prospectively evaluate the utility of TAaVR measurements would provide clarification of the appropriateness of this risk stratifications strategy. In addition to the small sample size, we treated the study population as both the training and test sets. Further study is warranted to validate our observation.
| CONCLUSION
Our findings suggest that TAaVR can be used to predict cardiac events in ICM and NICM patients with ICD implantation. We strongly recommend that TAaVR should not be neglected in the assessment of highrisk patients given its high sensitivity and negative predictive value for predicting cardiac events.
F I G U R E 3
Kaplan-Meier curve analysis of secondary endpoints. The effects of cardiac death, major ventricular arrhythmic events (MVAE), and hospitalization due to heart failure (HHF) on event-free survival were evaluated. A remarkable distinction was observed in MVAE (p < .01). Conversely, significant differences were not detected in cardiac death (p = .26) and HHF (p = .15)
